To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

NCT ID: NCT06389006

Last Updated: 2024-05-23

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 79 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-04-29
• Study Completion Date: 2026-12-31

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Toripalimab sequential chemotherapy as in patients with HR-positive, HER2-low breast cancer

Detailed Description

This is a single-arm, open-label, multicenter phase II clinical trial to evaluate the efficacy and safety of Disitamab Vedotin combined with Toripalimab sequential chemotherapy as neoadjuvant treatment in patients with HR-positive, HER2-low breast cancer

Conditions

Breast Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Disitamab Vedotin combined with Toripalimab sequential chemotherapy（Epirubicin +CTX）

Disitamab Vedotin combined with Toripalimab sequential chemotherapy arm

Group Type: EXPERIMENTAL

Disitamab Vedotin for Injection

Intervention Type: DRUG

2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed

Toripalimab

Intervention Type: DRUG

3.0 mg/kg, intravenous infusion, D1, every 2 weeks, every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed. Sequential therapy 3.0 mg/kg, intravenous infusion, D1, every 2 weeks,every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed.

Epirubicin

Intervention Type: DRUG

According to body surface area, 90mg/m2, intravenous infusion, D1, every 3 weeks, Every 6 weeks is a treatment cycle. A total of 12 weeks of treatment are performed.

Cyclophosphamide

Intervention Type: DRUG

According to body surface area,600mg/m2, intravenous infusion, D1, every 3 weeks , Every 6 weeks is a treatment cycle. A total of 12 weeks of treatment are performed

Interventions

Disitamab Vedotin for Injection

2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed

Intervention Type: DRUG

Toripalimab

3.0 mg/kg, intravenous infusion, D1, every 2 weeks, every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed. Sequential therapy 3.0 mg/kg, intravenous infusion, D1, every 2 weeks,every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed.

Intervention Type: DRUG

Epirubicin

According to body surface area, 90mg/m2, intravenous infusion, D1, every 3 weeks, Every 6 weeks is a treatment cycle. A total of 12 weeks of treatment are performed.

Intervention Type: DRUG

Cyclophosphamide

According to body surface area,600mg/m2, intravenous infusion, D1, every 3 weeks , Every 6 weeks is a treatment cycle. A total of 12 weeks of treatment are performed

Intervention Type: DRUG

Other Intervention Names

RC48; JS001; CTX

Eligibility Criteria

Inclusion Criteria

1. Voluntarily agree to participate in the study and sign the informed consent;

2. Age ≥18 years old (including the threshold value);

3. Histologically confirmed invasive breast cancer with clinical stage T1c-T2(≥2cm)cN1-2M0 or T3cN0-2M0;

4. As assessed by the research Center, the subjects can tolerate and plan to undergo radical surgery for breast cancer and have not previously received any anti-tumor systemic therapy for breast cancer;

5. Invasive breast tumor tissue with low HER2 expression confirmed by the central laboratory is defined as IHC 1+ or IHC 2+ expression of HER2 protein detected by immunohistochemistry (IHC), and no amplification detected by in situ hybridization (ISH) (according to the Breast Cancer HER2 Detection Guidelines 2019); Primary tumor specimens (wax pieces, slices or fresh tissues) can be provided for HER2 detection;

6. According to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) 2020 guidelines, tumor tissue estrogen receptor (ER) and progesterone receptor (PgR) expression ≥ 1%;

7. Histological grade (Nottingham grading system) G3 or G2 with ER expression

8. ECOG physical status 0 or 1;

9. At least one measurable lesion according to RECIST v1.1 standard;

10. Heart function:

1. New York Heart Association (NYHA) Grade < 3;

2. left ventricular ejection fraction ≥50%;

11. Bone marrow or organ function should meet the following criteria within 7 days before the study dose:

Hemoglobin ≥ 90g/L; Absolute neutrophil count (ANC) ≥1.5×109/L; Platelet ≥ 100 ×109/L; Serum total bilirubin ≤ 1.5 times the upper limit of normal value (ULN); Aspartate aminotransferase (AST) and glutamic pyruvic transaminase (ALT) ≤ 2.5 times the upper limit of normal value; International normalized ratio (INR) and activated partial thrombin time ≤ 1.5×ULN; Serum creatinine ≤ 1.5×ULN or creatinine clearance (CrCl) ≥ 50 mL/min according to Cockcroft-Gault formula method;

12. Fertile female subjects who meet the following conditions

1. A serum pregnancy test (minimum sensitivity 25 mIU/mL or equivalent units of β-human chorionic gonadotropin [β-hCG]) must be negative within 72 hours before the first dosing of the study intervention. Subjects with false positive results who are confirmed not to be pregnant are eligible for study.

2. Must agree to contraception for the duration of the study and for at least 6 months after the last dose of investigational drug.

3. Must agree not to breastfeed or donate eggs from the time of signing the informed consent until 6 months after the last dose of investigational drug.

4. If sexually active and likely to result in pregnancy, continuous use of at least 2 acceptable forms of contraception, at least 1 of which must be highly effective from the time of the informed consent and continue until at least 6 months after the last dosing of the investigational drug.

13. Fertile male subjects who meet the following conditions

1. Must agree not to donate sperm from the time of signing the informed consent until at least 4 months after the last dose of investigational drug.

2. If sexual activity with a fertile person is likely to result in pregnancy, continuous use of at least 2 acceptable forms of contraception, at least 1 of which must be highly effective from the time of the informed consent and continue until at least 4 months after the last dosing of the investigational drug.

3. If sexually active with a pregnant or breastfeeding patient, condom use must continue from informed consent until at least 4 months after the last dosing of the investigational drug.

14. Able to understand trial requirements, willing and able to follow trial and follow-up procedures.

Exclusion Criteria

1. Bilateral invasive breast cancer;

2. Previous history of invasive breast cancer;

3. Previously had carcinoma in situ of the breast and received adjuvant endocrine therapy within 5 years of surgery;

4. Use of the investigational drug or major surgery within 4 weeks prior to study dosing;

5. Have received or plan to receive live or attenuated vaccine within 4 weeks before the start of study dose;

6. Previous history of receiving allogeneic hematopoietic stem cell transplantation or organ transplantation;

7. Previous treatment with PD-(L)1, PD-L2, CTLA4 inhibitors and other Antibody-Drug Conjugates;

8. Uncontrolled or significant cardiovascular and cerebrovascular diseases

9. Presence of other treatable or serious lung diseases, including but not limited to active tuberculosis, interstitial lung disease, etc.;

10. Suffering from an active infection that requires systematic treatment;

11. Have active autoimmune diseases requiring systemic treatment within the past 2 years, allowing for relevant replacement therapy;

12. Have a clear past or present history of neurological or psychiatric disorders, including epilepsy or dementia;

13. Persistent ≥ grade 2 sensory or motor neuropathy;

14. In the judgment of the investigator, there is a serious concomitant disease that endangers the safety of the subject or interferes with the completion of the clinical study;

15. Positive HIV test result; Patients with active hepatitis B or C; Persistent coronavirus (COVID-19) infection;

16. Known hypersensitivity or delayed anaphylaxis to certain components of Disitamab Vedotin, and Toripalimab or Certain components of chemotherapy drugs or similar drugs used in the study;

17. Suffering from another malignancy within 5 years prior to signing the informed consent

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

RemeGen Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Leng Kang

Role: STUDY_DIRECTOR

RemeGen Co., Ltd.

Locations

Jiong Wu

Shanghai, Fudan University Shanghai Cancer Center, China

Site Status: RECRUITING

Countries

China

Central Contacts

Leng Kang

Role: CONTACT

kang.leng@remegen.com

+8610-58075763

Facility Contacts

Jiong Wu, Ph.D

Role: primary

Other Identifiers

RC48-C025

Identifier Type: -

Identifier Source: org_study_id